 Connection
Ann Thor to Quinazolines
This is a "connection" page, showing publications Ann Thor has written about Quinazolines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.416 |
|
|
|
-
Peng C, Catalano P, Zalcberg J, Thor AD, Weiner LM, Khandekar JD, Cohen D, Weinshel EL, O'Dwyer PJ, Benson AB. ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer. Oncologist. 2026 Apr 10; 31(5).
Score: 0.212
-
Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget. 2016 Jan 19; 7(3):2921-35.
Score: 0.104
-
Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol. 2015; 8(6):6143-56.
Score: 0.100
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|